Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Serono Austria GMBH
EVIDENCE-Umstellungsstudie (22 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 5: Basisdaten Abb. 6: EVIDENCE - Chronologie Abb. 7: Design - Patientenverteilung Aktuelles Bild - Abb. 8: Intervalle Abb. 9: Patientencharakteristik Abb. 10: Studienendpunkte Abb. 11: Umstellung Zum letzten Bild
Abbildung 8: Intervalle
EVIDENCE study design: pre-study MRI scan and clinical assessment; 2 relapses prior 2 years; randomize at SD1; monthly MRI gadolinium assessments until week 24; 3-monthly neurological examinations monthly AE/clinical assessment at time of MRI; monthly phone check between MRI dates to increase relapse ascertainment and reduce number of historical relapses reduced frequency of MRI scans after week 24; primary endpoint at week 24. Second phase from week 24-48; Post-48 week is variable because patients enrolled early continue on therapy until last patient enrolled completes week 48. Transition (T) is when patients switch from Avonex to Rebif.
 
Intervalle
Vorheriges Bild Nächstes Bild   


Abbildung 8: Intervalle
EVIDENCE study design: pre-study MRI scan and clinical assessment; 2 relapses prior 2 years; randomize at SD1; monthly MRI gadolinium assessments until week 24; 3-monthly neurological examinations monthly AE/clinical assessment at time of MRI; monthly phone check between MRI dates to increase relapse ascertainment and reduce number of historical relapses reduced frequency of MRI scans after week 24; primary endpoint at week 24. Second phase from week 24-48; Post-48 week is variable because patients enrolled early continue on therapy until last patient enrolled completes week 48. Transition (T) is when patients switch from Avonex to Rebif.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung